An Open Label Phase 2 Study of MLN0128 in Combination with Fulvestrant in Women with ERPositive/ HER2 Negative Advanced or Metastatic Breast Cancer that has Progressed During or AFter Aromatase Inhibitor Therapy
|Effective start/end date||1/1/17 → 1/30/23|
- MILLENNIUM PHARMACEUTICALS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.